The growth of the CIDP Market is heavily supported by improvements in diagnostic tools, such as Nerve Conduction Studies (NCS) and Electromyography (EMG). Early and accurate diagnosis is critical for CIDP, as it is often misdiagnosed as other forms of neuropathy; advanced imaging and cerebrospinal fluid (CSF) analysis are now being used more frequently to confirm cases. Technical details on diagnostic market trends can be found in the CIDP Market report.

People also ask: How is CIDP diagnosed? Can an EMG detect CIDP? Innovations in biomarker identification, such as measuring serum neurofilament light chain, are providing clinicians with more objective ways to monitor disease progression and response to therapy.

These diagnostic advancements allow for earlier intervention, which is essential for preventing permanent nerve damage. As these diagnostic kits become more standardized and widely available in regional hospitals, the "undiagnosed" patient pool is expected to shrink, directly contributing to increased market volume.